scholarly journals Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors

2019 ◽  
Vol Volume 12 ◽  
pp. 4713-4719 ◽  
Author(s):  
Yan-Shu Li ◽  
Wei Li ◽  
Qing-Sheng Zeng ◽  
Wei-Hua Fu
Keyword(s):  
High Risk ◽  
Treatment Regimen ◽  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Postoperative Prognosis ◽  
Stromal Tumors

Adjuvant Imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: A median follow-up of 44 months

2011 ◽  
Vol 104 (7) ◽  
pp. 760-764 ◽  
Author(s):  
Wei-Zhong Jiang ◽  
Guo-Xian Guan ◽  
Hui-Shan Lu ◽  
Ying-Hong Yang ◽  
De-Yong Kang ◽  
...  
Keyword(s):  
High Risk ◽  
Gastrointestinal Stromal Tumors ◽  
R0 Resection ◽  
Imatinib Treatment ◽  
Adjuvant Imatinib ◽  
Stromal Tumors

scholarly journals Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0193048 ◽  
Author(s):  
Michaela Angelika Ihle ◽  
Sebastian Huss ◽  
Wiebke Jeske ◽  
Wolfgang Hartmann ◽  
Sabine Merkelbach-Bruse ◽  
...  
Keyword(s):  
Cell Cycle ◽  
High Risk ◽  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Cell Cycle Regulators ◽  
Adjuvant Imatinib ◽  
Tp53 Mutations ◽  
Stromal Tumors

scholarly journals Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis

2016 ◽  
Vol 10 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Ryota Niikura ◽  
Takako Serizawa ◽  
Atsuo Yamada ◽  
Shuntaro Yoshida ◽  
Mariko Tanaka ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Imatinib Treatment ◽  
Efficacy And Safety ◽  
Tarry Stool ◽  
Dialysis Patients ◽  
Stromal Tumors ◽  
Duodenal Gist ◽  
Johnson Syndrome ◽  
Old Japanese ◽  
Steven Johnson Syndrome

The number of cancer patients undergoing dialysis has been increasing, and the number of these patients on chemotherapy is also increasing. Imatinib is an effective and safe therapy for KIT-positive gastrointestinal stromal tumors (GIST), but the efficacy and safety of imatinib in dialysis patients remain unclear. Because clinical trials have not been conducted in this population, more investigations are required. We report on a 75-year-old Japanese man undergoing dialysis who presented with massive tarry stool from a duodenal GIST. The duodenal GIST was 14 cm in diameter with multiple liver and bone metastases. The patient underwent an urgent pancreaticoduodenectomy to achieve hemostasis. After surgery, he was administered imatinib 400 mg/day. No severe adverse event including myelosuppression, congestive heart failure, liver functional impairment, intestinal pneumonia, or Steven-Johnson syndrome occurred, and the liver metastasis remained stable for 4 months. During chemotherapy, hemodialysis continued three times per week without adverse events. We suggest that regular-dose imatinib is an effective and safe treatment in patients with GIST undergoing dialysis. In addition, we present a literature review of the effectiveness and safety of imatinib treatment in dialysis patients.

scholarly journals Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

JAMA Oncology ◽  
2020 ◽  
Vol 6 (8) ◽  
pp. 1241 ◽  
Author(s):  
Heikki Joensuu ◽  
Mikael Eriksson ◽  
Kirsten Sundby Hall ◽  
Annette Reichardt ◽  
Barbara Hermes ◽  
...  
Keyword(s):  
High Risk ◽  
Gastrointestinal Stromal Tumors ◽  
Survival Outcomes ◽  
Adjuvant Imatinib ◽  
Stromal Tumors
Sign in / Sign up

Export Citation Format

Share Document